Tag Archives: Allena Pharmaceuticals

Analysts Offer Insights on Healthcare Companies: Allena Pharmaceuticals (NASDAQ: ALNA) and Beyondspring (NASDAQ: BYSI)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Allena Pharmaceuticals (ALNA – Research Report) and Beyondspring (BYSI – Research Report) with bullish sentiments. Allena Pharmaceuticals (ALNA) In a report issued

Wedbush Thinks Allena Pharmaceuticals’ Stock is Going to Recover

Wedbush analyst Liana Moussatos reiterated a Buy rating on Allena Pharmaceuticals (ALNA – Research Report) today and set a price target of $18.00. The company’s shares closed last Wednesday at $1.17, close to its 52-week low of $0.53. According to

Ladenburg Thalmann & Co. Reiterates Their Buy Rating on Allena Pharmaceuticals (ALNA)

In a report issued on May 14, Matthew Kaplan from Ladenburg Thalmann & Co. reiterated a Buy rating on Allena Pharmaceuticals (NASDAQ: ALNA), with a price target of $8.00. The company’s shares closed last Wednesday at $1.42, close to its

Roth Capital Reiterates Buy on Allena Pharmaceuticals Shares, Sees 675% Upside For The Stock

In a research report released on Thursday, Roth Capital analyst Yasmeen Rahimi reiterated a Buy rating on Allena Pharmaceuticals (NASDAQ:ALNA)with a price target of $11, which implies an upside of 675% from current levels. According to TipRanks.com, which measures analysts’

Wedbush Keeps Their Buy Rating on Allena Pharmaceuticals (ALNA)

Wedbush analyst Liana Moussatos reiterated a Buy rating on Allena Pharmaceuticals (ALNA – Research Report) today and set a price target of $26.00. The company’s shares closed last Tuesday at $2.71. According to TipRanks.com, Moussatos is a 4-star analyst with

Allena Pharmaceuticals (ALNA) Gets a Buy Rating from B.Riley FBR

In a report released today, Mayank Mamtani from B.Riley FBR reiterated a Buy rating on Allena Pharmaceuticals (ALNA – Research Report), with a price target of $4.00. The company’s shares closed last Monday at $0.59, close to its 52-week low